Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-L1 and PD-L2 Peptide Vaccination in Relapsed Follicular Lymphoma
NCT03381768Phase 1Completed
- Start
- Dec 2017
- Primary completion
- Feb 2020
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IO120 and IO103 + Montanide in follicular lymphoma (FL). Primary endpoint: Adverse events evaluated by CTCAE 4.03 at 1 year. Started Dec 2017; status: completed.
02
Drugs
IO120IO103 + Montanide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03381768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03381768.